Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label randomized, controlled, multicenter, phase II trial with two arms.
Patients with metastatic TTF-1 negative, treatment-naive lung adenocarcinoma without
actionable genomic alterations are randomized in a 1:1 manner to investigate the efficiency
of atezolizumab, carboplatin and nab-paclitaxel (Arm A) versus pembrolizumab,
cis-/carboplatin and pemetrexed (Arm B) as first-line treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Nikolaj Frost MD
Collaborators:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Roche Pharma AG